Neo-Cytamen (Hydroxocobalamin Chloride)

Neo-Cytamen is used to correct vitamin B12 deficiency and related disorders by providing the active cobalamin needed for normal hematologic and neurologic function.

• Vitamin B12 deficiency: restores normal red blood cell production and neurological health.
• Pernicious anemia: compensates for intrinsic factor deficiency, improving hematologic parameters.
• Cyanide poisoning: binds cyanide ions to form cyanocobalamin, facilitating detoxification.

• Hydroxocobalamin acts as a co‑factor for the enzymes methionine synthase and methylmalonyl‑CoA mutase, enabling the conversion of homocysteine to methionine and the metabolism of odd‑chain fatty acids. By supplying cobalamin directly to cells, it supports DNA synthesis, myelin formation, and erythropoiesis. In cyanide exposure, the molecule forms a stable complex with cyanide, converting it to cyanocobalamin, which is then excreted.

Intramuscular hydroxocobalamin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site pain: mild discomfort or soreness at the injection site.
• Redness or swelling: localized erythema or edema.
• Headache: transient headache following administration.
• Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with airway compromise.
• Hypotension: sudden drop in blood pressure.
• Thrombophlebitis: inflammation of a vein with clot formation.
• Severe skin rash: widespread urticaria or exfoliative dermatitis.

When prescribing Neo‑Cytamen, clinicians should consider several safety measures to minimize risk.

• Assess B12 status: confirm deficiency or indication before administration.
• Monitor for allergic reactions: observe patient after injection for signs of hypersensitivity.
• Use caution in renal impairment: adjust monitoring as hydroxocobalamin is renally excreted.
• Avoid concurrent intramuscular injections at same site: reduce tissue irritation.
• Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Hydroxocobalamin can influence the activity of certain drugs, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Metformin: may mask B12 deficiency, necessitating regular monitoring.
• Nitrous oxide anesthesia: can inactivate cobalamin, reducing efficacy of hydroxocobalamin therapy.
• Chemotherapeutic agents (e.g., methotrexate): high‑dose vitamin B12 may interfere with drug action.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors: reduce gastric acidity, potentially decreasing oral B12 absorption (relevant for overall B12 status).
• Anticonvulsants (phenytoin, carbamazepine): may increase B12 metabolism, requiring periodic level checks.
• Folate supplements: high folate can mask hematologic signs of B12 deficiency, necessitating combined monitoring.